Tellus BioVentures

Tellus BioVentures targets seed-stage life-science companies, entering at formation or first institutional round. Public records indicate the firm focuses on ventures that are pre-revenue but have reached proof-of-concept in a relevant validation layer — in silico, in vitro, or in an animal model. The firm's posture is to underwrite specific therapeutic or diagnostic theses at inception rather than index the broader sector.

The firm's publicly observable activity suggests it structures investments as direct equity positions and is willing to lead or co-lead seed rounds alongside other specialist health-tech investors. Tellus appears to favor capital-efficient models with milestones clearly defined within 18- to 24-month funding tranches, indicating a hands-on, high-conviction approach to portfolio construction.

Tellus BioVentures targets therapeutics, diagnostics, and care-delivery platforms at the intersection of deep science and computation. Its sector coverage includes biotech, medical devices, and health-AI — specifically machine-learning applications for drug discovery, clinical-trial optimization, and precision-medicine workflows. The firm positions itself where biological breakthroughs meet unmet medical need.

Tellus BioVentures is headquartered in Florida, which positions it to source from founders emerging from the southeastern United States' growing academic-medical corridors — institutions such as the University of Florida, University of Miami, and the Moffitt Cancer Center ecosystem. The firm maintains connectivity to coastal venture hubs while exploiting a geographic advantage in a region that is often less competitively shopped by Boston- and San Francisco-based biotech seed funds.

Tellus BioVentures' specific fund structure is not publicly disclosed, consistent with many sub-institutional emerging managers in biotech seed. It likely operates a single general-partner entity with a lean operating team. Without a disclosed institutional limited-partner base, the vehicle is plausibly capitalized by high-net-worth individuals, self-funded by the general partners, or structured on a deal-by-deal basis using special-purpose vehicles, though this cannot be confirmed from public record.